Hope S. Rugo
0000-0001-6710-4814
Publication & Citation Trends
Publications
0 total
Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2− bone-only metastatic breast cancer
Cited by 0
Semantic Scholar
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors
Cited by 0
Semantic Scholar
Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer.
Cited by 0
Semantic Scholar
Abstract PS1-11-10: Real-world progression-free survival 2 (rwPFS2) and tumor response with CDK4/6is + aromatase inhibitor (AI) in patients (pts) with HR+/HER2- metastatic breast cancer (MBC)
Cited by 0
Semantic Scholar
Abstract GS3-09: Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor
Cited by 0
Semantic Scholar
Abstract C040: Sustained lymphopenia during neoadjuvant chemo-immunotherapy is associated with worse outcomes in early triple-negative breast cancer
Cited by 0
Semantic Scholar
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer in US routine clinical practice
Cited by 0
Semantic Scholar
Research Topics
Advanced Breast Cancer Therapies
(719)
Cancer Treatment and Pharmacology
(466)
HER2/EGFR in Cancer Research
(433)
Breast Cancer Treatment Studies
(337)
Cancer Genomics and Diagnostics
(196)
Affiliations
University College Dublin
Université Paris-Sud
Twitter (United States)
Goethe University Frankfurt
University of Southern California